418 related articles for article (PubMed ID: 30586267)
1. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome.
Saini A; Ferguson C; Salkey K
J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267
[TBL] [Abstract][Full Text] [Related]
2. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
3. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
4. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
5. Behçet's disease and complex aphthosis.
Ghate JV; Jorizzo JL
J Am Acad Dermatol; 1999 Jan; 40(1):1-18; quiz 19-20. PubMed ID: 9922007
[TBL] [Abstract][Full Text] [Related]
6. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Atienza-Mateo B; Martín-Varillas JL; Graña J; Espinosa G; Moriano C; Pérez-Sandoval T; García-Armario MD; Castellví I; Román-Ivorra JA; Olivé A; Ybáñez A; Martinez-Ferrer A; Narváez J; Romero-Yuste S; Ojeda S; Ros I; Loricera J; Calvo-Río V; Castañeda S; Gonzalez-Gay MA; Blanco R;
Clin Exp Rheumatol; 2020; 38 Suppl 127(5):69-75. PubMed ID: 33331268
[TBL] [Abstract][Full Text] [Related]
7. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
10. [Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].
Fourmond S; Gutierrez B; Gourin MP; Delaumenie S; Ly KH
Rev Med Interne; 2022 May; 43(5):312-315. PubMed ID: 35219509
[TBL] [Abstract][Full Text] [Related]
11. Behçet's disease and oral ulcers.
Georgaklis CC
Dent Today; 2004 Mar; 23(3):14. PubMed ID: 15060906
[No Abstract] [Full Text] [Related]
12. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
13. Complex aphthosis and Behçet's disease.
McCarty MA; Garton RA; Jorizzo JL
Dermatol Clin; 2003 Jan; 21(1):41-8, vi. PubMed ID: 12622267
[TBL] [Abstract][Full Text] [Related]
14. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis of colitis in Behçet's syndrome (author's transl)].
Meryn S; Ferenci P; Pamperl H; Lenzhofer R; Salomonowitz E; Wewelka F
Leber Magen Darm; 1982 Feb; 12(1):16-9. PubMed ID: 7070192
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
[TBL] [Abstract][Full Text] [Related]
17. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study.
Nanke Y; Kamatani N; Okamoto T; Ogiuchi H; Kotake S
Drugs R D; 2008; 9(6):455-9. PubMed ID: 18989994
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease.
Lopalco G; Venerito V; Leccese P; Emmi G; Cantarini L; Lascaro N; Di Scala G; Fabiani C; Rigante D; Iannone F
Ann Rheum Dis; 2019 Dec; 78(12):1736-1737. PubMed ID: 31401548
[No Abstract] [Full Text] [Related]
19. Effectiveness of apremilast against Behçet's disease-associated mucocutaneous and joint involvement confirmed through switching from adalimumab.
Azuma N; Matsui K
Clin Exp Rheumatol; 2022 Sep; 40(8):1605-1606. PubMed ID: 36106543
[No Abstract] [Full Text] [Related]
20. Aphtous stomatitis in a patient with Behçet's disease and HIV was associated with an increased HIV load.
Mercié P; Viallard JF; Cipriano C; Tchamgoué S; Leng B; Pellegrin JL
Clin Exp Rheumatol; 2002; 20(4 Suppl 26):S54. PubMed ID: 12371637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
